These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21435667)

  • 1. Biomarkers to tailor chemoradiation therapies.
    Guzzetta AA; Ahuja N
    J Surg Res; 2012 Apr; 173(2):243-5. PubMed ID: 21435667
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.
    Dreussi E; Cecchin E; Polesel J; Canzonieri V; Agostini M; Boso C; Belluco C; Buonadonna A; Lonardi S; Bergamo F; Gagno S; De Mattia E; Pucciarelli S; De Paoli A; Toffoli G
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectal Cancer: Time for Precision Medicine?
    Weiser MR
    Ann Surg Oncol; 2016 Jan; 23(1):12-5. PubMed ID: 26323994
    [No Abstract]   [Full Text] [Related]  

  • 5. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer.
    Grimminger PP; Brabender J; Warnecke-Eberz U; Narumiya K; Wandhöfer C; Drebber U; Bollschweiler E; Hölscher AH; Metzger R; Vallböhmer D
    J Surg Res; 2010 Nov; 164(1):e61-6. PubMed ID: 20863523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.
    Dayde D; Tanaka I; Jain R; Tai MC; Taguchi A
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.
    Pezzolo E; Modena Y; Corso B; Giusti P; Gusella M
    Eur J Clin Pharmacol; 2015 May; 71(5):529-39. PubMed ID: 25740678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs as biomarkers of multimodal treatment for rectal cancer.
    Waldron RM; Moloney BM; Gilligan K; Lowery AJ; Joyce MR; Holian E; Kerin MJ; Miller N
    Br J Surg; 2021 Aug; 108(8):e260-e261. PubMed ID: 33880499
    [No Abstract]   [Full Text] [Related]  

  • 10. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation.
    Gordon MA; Gil J; Lu B; Zhang W; Yang D; Yun J; Schneider S; Groshen S; Iqbal S; Press OA; Rhodes K; Lenz HJ
    Pharmacogenomics; 2006 Jan; 7(1):67-88. PubMed ID: 16354126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients.
    Shalaby SM; El-Shal AS; Abdelaziz LA; Abd-Elbary E; Khairy MM
    Gene; 2018 Feb; 644():66-73. PubMed ID: 29080834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Lim SH; Chua W; Henderson C; Ng W; Shin JS; Chantrill L; Asghari R; Lee CS; Spring KJ; de Souza P
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):67-80. PubMed ID: 26032919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
    Bohanes P; Rankin CJ; Blanke CD; Winder T; Ulrich CM; Smalley SR; Rich TA; Martensen JA; Benson AB; Mayer RJ; Cripps CM; Danenberg K; Makar KW; Zhang W; Benedetti JK; Lenz HJ
    Clin Cancer Res; 2015 Apr; 21(7):1583-90. PubMed ID: 25589620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
    Lee YE; He HL; Shiue YL; Lee SW; Lin LC; Wu TF; Chang IW; Lee HH; Li CF
    Tumour Biol; 2015 Sep; 36(10):7675-83. PubMed ID: 25929810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness.
    Fang S; Vaysse A; Brossard M; Wang Y; Deng D; Liu Q; Zhang P; Xu K; Li M; Feng R; Liu H; Dang Y; Chen W; Prieto V; Gershenwald JE; Ross MI; Matejka B; Malke J; Haydu LE; Reveille JD; Sui D; Bassett RL; Koshkina N; Avril MF; Lu M; Wei Q; Demenais F; Amos CI; Lee JE
    J Invest Dermatol; 2017 Jan; 137(1):253-257. PubMed ID: 27506587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.